NYSEAMERICAN:VNRX VolitionRx (VNRX) Stock Price, News & Analysis → A.I. is a Tidal Wave - Here’s What to Buy (From Chaikin Analytics) (Ad) Free VNRX Stock Alerts $0.90 +0.03 (+3.45%) (As of 12:18 PM ET) Add Compare Share Share Today's Range$0.90▼$0.9150-Day Range N/A52-Week Range$0.55▼$2.10Volume32,258 shsAverage Volume216,184 shsMarket Capitalization$56.60 millionP/E RatioN/ADividend YieldN/APrice Target$2.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipShort Interest Get VolitionRx alerts: Email Address VolitionRx MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside123.2% Upside$2.00 Price TargetShort InterestHealthy0.70% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.50) to ($0.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.34 out of 5 stars 3.5 Analyst's Opinion Consensus RatingVolitionRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageVolitionRx has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.70% of the outstanding shares of VolitionRx have been sold short.Short Interest Ratio / Days to CoverVolitionRx has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in VolitionRx has recently decreased by 10.66%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldVolitionRx does not currently pay a dividend.Dividend GrowthVolitionRx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VNRX. Previous Next 1.1 News and Social Media Coverage Search Interest1 people have searched for VNRX on MarketBeat in the last 30 days. MarketBeat Follows1 people have added VolitionRx to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, VolitionRx insiders have not sold or bought any company stock.Percentage Held by Insiders15.40% of the stock of VolitionRx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 10.14% of the stock of VolitionRx is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for VolitionRx are expected to grow in the coming year, from ($0.50) to ($0.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of VolitionRx is -1.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of VolitionRx is -1.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceHave You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...This strange new device to protect us against that A.I. threat... About VolitionRx Stock (NYSEAMERICAN:VNRX)VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.Read More VNRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VNRX Stock News HeadlinesApril 23, 2024 | finance.yahoo.comNu.Q® Vet Cancer Test launched in-clinic in U.S. and Europe through AntechMarch 28, 2024 | seekingalpha.comVolitionRx Limited (VNRX) Q4 2023 Earnings Call TranscriptMay 2, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.March 27, 2024 | finance.yahoo.comVolitionRx Limited (AMEX:VNRX) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | msn.comTELA Bio launches Liquifix surgical devices in the U.S.March 20, 2024 | finance.yahoo.comVolition and Fujifilm Vet Systems Launch Nu.Q® Vet Cancer Test in JapanFebruary 2, 2024 | finance.yahoo.comVolition to Share Nu.Q® NETs Strategy Update at Upcoming WebinarJanuary 6, 2024 | proactiveinvestors.comVolitionRx has 'compelling plans' to advance veterinary care in 2024May 2, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.January 4, 2024 | finance.yahoo.comVolition Issues Business Review 2023January 3, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Medios AG (OtherMEDOF), Universal Health (UHS) and VolitionRX (VNRX)November 14, 2023 | finance.yahoo.comVolitionRx Limited Announces Third Quarter 2023 Financial Results and Business UpdateNovember 2, 2023 | finance.yahoo.comVNRX: Breakthrough Cancer Detection Method Disclosed at ESMO and in a Webinar - preliminary proof of concept work indicates simple blood test should be able to detect several types of cancer, potentially at Stages I & IINovember 1, 2023 | msn.comVolitionRX (VNRX) Price Target Increased by 7.93% to 3.76October 31, 2023 | msn.comEF Hutton Initiates Coverage of VolitionRX (VNRX) with Buy RecommendationOctober 28, 2023 | markets.businessinsider.comCantor Fitzgerald Reaffirms Their Buy Rating on VolitionRX (VNRX)October 19, 2023 | proactiveinvestors.comVolitionRx hails study showing Nu.Q NETs promise as biomarker for septic shockOctober 19, 2023 | finance.yahoo.comMeasuring Nucleosomes Using Nu.Q® NETs is a Promising Biomarker for Septic ShockOctober 18, 2023 | proactiveinvestors.comVolitionRx welcomes US Ambassador to Belgium for exclusive tour of research facilitiesOctober 18, 2023 | finance.yahoo.comUS Ambassador Adler visits Belgian VolitionOctober 16, 2023 | proactiveinvestors.comVolitionRx to present cancer detection abstracts at European oncology conferenceOctober 16, 2023 | finance.yahoo.comVolition Presents Three Cancer Detection Abstracts at ESMO 2023October 13, 2023 | proactiveinvestors.comVolitionRx holds roundtable on sepsis managementOctober 13, 2023 | finance.yahoo.comVolition Publishes Key Opinion Leader Roundtable Report on NETs in SepsisOctober 4, 2023 | proactiveinvestors.comVolitionRx to unveil new cancer detection method insights at upcoming webinarOctober 2, 2023 | finance.yahoo.comVolition to Reveal New Cancer Detection Method Insights at Upcoming WebinarSeptember 22, 2023 | msn.comVolitionRx, Avalo Therapeutic among healthcare moversSee More Headlines Receive VNRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VolitionRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/25/2024Today5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Diagnostics & Research Sub-IndustryN/A Current SymbolNYSEAMERICAN:VNRX Previous SymbolNYSEMKT:VNRX CUSIPN/A CIKN/A Webwww.volitionrx.com Phone(646) 650-1351Fax65 32 8172 5651Employees110Year FoundedN/APrice Target and Rating Average Stock Price Target$2.00 High Stock Price Target$2.00 Low Stock Price Target$2.00 Potential Upside/Downside+130.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,270,000.00 Net Margins-9,158.31% Pretax Margin-9,257.43% Return on Equity-15,493.47% Return on Assets-149.54% Debt Debt-to-Equity RatioN/A Current Ratio0.69 Quick Ratio0.69 Sales & Book Value Annual Sales$310,000.00 Price / Sales176.50 Cash FlowN/A Price / Cash FlowN/A Book Value($0.05) per share Price / Book-17.32Miscellaneous Outstanding Shares63,180,000Free Float53,450,000Market Cap$54.71 million OptionableNot Optionable Beta1.59 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Martin Charles Faulkes Ph.D. (Age 80)Executive Chairman Comp: $239.51kMr. Cameron Reynolds MBA (Age 53)Founder, CEO, President & Director Comp: $572.43kDr. Gaetan Michel Ph.D. (Age 50)Chief Operating Officer Comp: $518.15kDr. Salvatore Thomas Butera DVM (Age 72)Chief Executive Officer of Volition Veterinary Diagnostics Development LLC Comp: $477.25kMr. Terig Hughes (Age 53)CFO & Treasurer Comp: $338.74kDr. Jacob Vincent Micallef MBA (Age 68)Ph.D., Chief Scientific Officer Comp: $571.55kMr. Nicholas Plummer (Age 53)Group General Counsel Ms. Louise Batchelor Day (Age 52)Group Chief Marketing & Communications Officer Mr. Thomas BygottSales & Marketing DirectorMr. Gael Forterre M.B.A. (Age 42)Chief Commercial Officer More ExecutivesKey CompetitorsGenetronNASDAQ:GTHAcerus PharmaceuticalsOTCMKTS:TRLPFEntera BioNASDAQ:ENTXImmix BiopharmaNASDAQ:IMMXGenenta ScienceNASDAQ:GNTAView All CompetitorsInsidersCameron John ReynoldsBought 10,000 shares on 8/16/2023Total: $12,200.00 ($1.22/share)Salvatore Thomas ButeraBought 10,000 shares on 6/2/2023Total: $15,900.00 ($1.59/share)View All Insider Transactions VNRX Stock Analysis - Frequently Asked Questions Should I buy or sell VolitionRx stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for VolitionRx in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" VNRX shares. View VNRX analyst ratings or view top-rated stocks. What is VolitionRx's stock price target for 2024? 1 analysts have issued twelve-month price targets for VolitionRx's stock. Their VNRX share price targets range from $2.00 to $2.00. On average, they anticipate the company's share price to reach $2.00 in the next year. This suggests a possible upside of 123.2% from the stock's current price. View analysts price targets for VNRX or view top-rated stocks among Wall Street analysts. How were VolitionRx's earnings last quarter? VolitionRx Limited (NYSEAMERICAN:VNRX) issued its earnings results on Monday, March, 25th. The medical research company reported ($0.11) EPS for the quarter. The medical research company earned $0.24 million during the quarter, compared to the consensus estimate of $0.50 million. VolitionRx had a negative trailing twelve-month return on equity of 15,493.47% and a negative net margin of 9,158.31%. What other stocks do shareholders of VolitionRx own? Based on aggregate information from My MarketBeat watchlists, some companies that other VolitionRx investors own include Chesapeake Energy (CHKAQ), Bausch Health Companies (BHC), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL), CRISPR Therapeutics (CRSP), TherapeuticsMD (TXMD), ADMA Biologics (ADMA) and Bausch Health Companies (BHC). How do I buy shares of VolitionRx? Shares of VNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:VNRX) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersAI finds its first serious applicationWall Street StarRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsA once-in-a-century investment opportunityStansberry ResearchProtect Your Bank Account Before It’s Too LateWeiss RatingsYour bank is lying to you.MyBankTracker Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VolitionRx Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
